Abstract
Apolipoprotein B48 (apoB48)-containing triglyceride-rich lipoproteins are atherogenic and therefore it is important to understand factors that regulate their metabolism in the intestine. Insulin resistant states are associated with increased intestinal output of apo B48, but the mechanistic studies explaining this overproduction have relied heavily on models of diet-induced insulin resistance. There is evidence that glucagon-like peptide (GLP) secretion is diminished in insulin resistant and diabetic states, which may have implications for postprandial lipid secretion. This review presents a survey of studies on GLPs and intestinal lipoprotein metabolism, along with some insights into the net physiological significance of GLP action in postprandial lipoprotein metabolism. Studies with GLP-1 receptor agonists and dipeptidyl peptidase-IV inhibitors have indicated that GLP-1 in pharmacological and physiological doses can inhibit intestinal TRL production. On the other hand, GLP-2 has an acute stimulatory effect on intestinal apoB48 secretion. Modulating GLP action may serve as a strategy to improve postprandial dyslipidemia in insulin resistant states.
Keywords: Apolipoprotein B48, insulin resistance, postprandial dyslipidemia
Cardiovascular & Hematological Disorders-Drug Targets
Title:Regulation of Intestinal Chylomicron Production by Glucagon-Like Peptides
Volume: 12 Issue: 2
Author(s): Joanne Hsieh and Khosrow Adeli
Affiliation:
Keywords: Apolipoprotein B48, insulin resistance, postprandial dyslipidemia
Abstract: Apolipoprotein B48 (apoB48)-containing triglyceride-rich lipoproteins are atherogenic and therefore it is important to understand factors that regulate their metabolism in the intestine. Insulin resistant states are associated with increased intestinal output of apo B48, but the mechanistic studies explaining this overproduction have relied heavily on models of diet-induced insulin resistance. There is evidence that glucagon-like peptide (GLP) secretion is diminished in insulin resistant and diabetic states, which may have implications for postprandial lipid secretion. This review presents a survey of studies on GLPs and intestinal lipoprotein metabolism, along with some insights into the net physiological significance of GLP action in postprandial lipoprotein metabolism. Studies with GLP-1 receptor agonists and dipeptidyl peptidase-IV inhibitors have indicated that GLP-1 in pharmacological and physiological doses can inhibit intestinal TRL production. On the other hand, GLP-2 has an acute stimulatory effect on intestinal apoB48 secretion. Modulating GLP action may serve as a strategy to improve postprandial dyslipidemia in insulin resistant states.
Export Options
About this article
Cite this article as:
Hsieh Joanne and Adeli Khosrow, Regulation of Intestinal Chylomicron Production by Glucagon-Like Peptides, Cardiovascular & Hematological Disorders-Drug Targets 2012; 12 (2) . https://dx.doi.org/10.2174/1871529X11202020092
DOI https://dx.doi.org/10.2174/1871529X11202020092 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Postprandial Lipemia in Children and Adolescents
Current Vascular Pharmacology Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Current Vascular Pharmacology Low Baseline Urine Creatinine Excretion Rate Predicts Poor Outcomes among Critically Ill Acute Stroke Patients
Current Neurovascular Research The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy
Current Pharmaceutical Design Genetics in Diabetic Retinopathy: Current Concepts and New Insights
Current Genomics Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Editorial (Hot Topic: Metabolic Syndrome and Cardiovascular Health: A Look Beyond the Horizon)
Current Pharmaceutical Design Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Allele Frequencies of Two Main Metformin Transporter Genes: SLC22A1 rs628031 A>G and SLC47A1 rs2289669 G>A among the Javanese Population in Indonesia
Current Pharmacogenomics and Personalized Medicine Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV Resistant Glucagon-like Peptide-1 Analogues
Protein & Peptide Letters Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer's Disease
Current Alzheimer Research Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Current Pharmaceutical Design Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews <i>Laurus Nobilis</i> Linn. Inhibits Polyol Pathway Enzymes: Strategy for Managing Diabetic Complications
Current Enzyme Inhibition Obesity and Diabetes Gene Discovery Approaches
Current Pharmaceutical Design Inappropriate Antidopaminergic Drug Use in Parkinson’s Disease Inpatients
Current Drug Therapy Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews